Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
Showcasing at AAO 2025: NEW 510k CLEARANCE SUPPORTS MORE INFORMED DECISION MAKING & PATHOLOGY DETECTION: Showcasing optical coherence tomography angiography…
LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN)…
August 21, 2025 01:30 ET | Source: NICOX SA Press Release Nicox Announces Positive Results from the NCX 470 Phase…